BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-82@pharmaconomics
DTSTAMP:20260707T034114Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:DSCOY Phase 3 — Ifinatamab deruxtecan
DESCRIPTION:Phase 3 trial results for Ifinatamab deruxtecan in Small Cell Lung Cancer are due Apr 30\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT06203210\n\nTrack it: https://www.pharmaconomics.com/e/82
URL:https://www.pharmaconomics.com/e/82
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:DSCOY catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR